Publication | Open Access

C-Aryl glucosides substituted at the 4′-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

Molecular PharmacologyDiabetes ManagementBiochemistryMedicineDiabetesType 2Diabetic Kidney DiseaseDiabetes MellitusC-aryl GlucosidesPharmacologyRenal PharmacologyDrug Discovery